| Feature Type | Standardized | Nominal ANOVA | ||||
|---|---|---|---|---|---|---|
| mRNA | BRD-K29313308 | CTRPv2 | pan-cancer | AAC | -0.0034 | 0.9 |
| mRNA | KIN001-266 | GDSC1000 | pan-cancer | AAC | 0.0032 | 0.9 |
| mRNA | tivozanib | GDSC1000 | pan-cancer | AAC | 0.0032 | 0.9 |
| mRNA | VX-702 | GDSC1000 | pan-cancer | AAC | 0.0033 | 0.9 |
| mRNA | 17-AAG | GDSC1000 | pan-cancer | AAC | 0.0029 | 0.9 |
| mRNA | Vandetanib | CTRPv2 | pan-cancer | AAC | -0.0032 | 0.9 |
| mRNA | SKI-II | CTRPv2 | pan-cancer | AAC | -0.003 | 0.9 |
| mRNA | salermide:PLX-4032 (12:1 mol/mol) | CTRPv2 | pan-cancer | AAC | 0.003 | 0.9 |
| mRNA | CD-1530 | CTRPv2 | pan-cancer | AAC | 0.003 | 0.9 |
| mRNA | Z-LLNle-CHO | GDSC1000 | pan-cancer | AAC | -0.0039 | 0.9 |